Health
First comparative data of encorafenib and paradox breaker inhibitors in BRAF mutant CRC – News-Medical.Net
Oncotarget Volume 11, Issue 34 features Figure 1, “BRAF inhibitor-induced changes in cell viability,” by Pickles, et al which reported that the BEACON CRC trial demonstrated a survival advantage over chemotherapy for a combination of targeted agents comprisin…
Oncotarget Volume 11, Issue 34 features Figure 1, “BRAF inhibitor-induced changes in cell viability,” by Pickles, et al. which reported that the BEACON CRC trial demonstrated a survival advantage over chemotherapy for a combination of targeted agents comprising the potent BRAF inhibitor encorafenib together with cetuximab and binimetinib.
Resistance to BRAF inhibition in CRC arises in part through the generation and activation of RAF dimers resulting in MEK-ERK pathway reactivation.
The Oncota…
-
General13 hours agoChina and Philippines trade blame over latest South China Sea clash
-
General13 hours agoSmall plane crashes into San Diego neighbourhood, setting homes and vehicles on fire
-
Noosa News22 hours agoConfusion over licensing and access to hunting grounds under WA’s strict gun laws
-
General13 hours agoOf saints and sinners | The Spectator Australia